Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden

You may be eligible if

• 1. Diagnosis of MS
• 1. Active relapsing remitting MS (RRMS) as evidenced by presence of ≥ 1 clinically documented relapse in the past 12 months or ≥2 clinically documented relapses in the last 24 months.
• 2. Secondary progressive MS with clinical progression as evidenced by an increase of 1 EDSS point (or 0,5 p if EDSS ≥ 5 at time for study start) in the last year or evidenced by ≥1 relapse or ≥ GEL at MRI performed within the last year.
• 3. Primary progressive MS with clinical progression as evidenced by an increase of 1 EDSS point (or 0,5 p if EDSS ≥ 5 at time for study start) in the last year.
• 2. Age\_ 18-65 years
• 3. Disease duration: 2-20 years
• 4. EDSS 3,0-7,0
• 2. Treatment with any immunosuppressive therapy, including natalizumab and fingolimod, within the 3 months prior to randomization
• 3. Treatment with interferon-beta or glatiramer acetate within the 30 days prior to randomization
• 4. Treatment with corticosteroids within the 30 days prior to randomization
• 5. Relapse occurred during the 60 days prior to randomization
• 6. Previous history of a malignancy other than basal cell carcinoma of the skin or carcinoma in situ that has been in remission for more than one year
• 7. Severely limited life expectancy by another co-morbid illness
• 8. Active or chronic severe infection.
• 9. History of previous diagnosis of myelodysplasia or previous hematologic disease or current clinically relevant abnormalities of white blood cell counts
• 10. Pregnancy or risk or pregnancy (this includes patients that are unwilling to practice active contraception during the duration of the study)
• 11. eGFR \< 60 mL/min/1.73m2 or known renal failure or inability to undergo MRI examination.
• 12. Inability to give written informed consent in accordance with research ethics board guidelines